expanded-collaboration-MD-Anderson

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer  Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC)  The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim ’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news